----
Current ValuationThe current P/E ratio is -2.30, within the reasonable range, cheaper than 29.5% of the time in the past 1 years, and the industry ranks 24/38, the industry Median -0.93.
-2.3xP/E
$2.80Stock price
$-1.22Earnings per share
-2.3xP/E
Stock price$2.80Earnings per share$-1.22
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -3.27x
- Typical range
- -7.00x–-1.14x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
013263952
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
| Name/Symbol | |||
|---|---|---|---|
HTFLUSHeartFlow | -41.66x | 74.45% | $4.93B |
SDGRUSSchrodinger | -32.77x | 16.60% | $1.78B |
CERTUSCertara | -23.04x | 2,116.80% | $1.58B |
TDOCUSTeladoc | -6.49x | 21.86% | $1.15B |
MDRXUSVeradigm | -- | -- | $842.92M |
SOPHUSSophia Genetics SA | -7.74x | 19.83% | $625.69M |
EVHUSEvolent Health | -1.06x | 84.41% | $542.68M |
CTEVUSClaritev | -1.41x | 12.62% | $398.27M |
AMWLUSAmerican Well | -2.95x | 57.74% | $230.81M |
DHUSDefinitive Healthcare | -0.93x | 28.60% | $156.43M |
HCATUSHealth Catalyst | -0.48x | 4.22% | $127.18M |
LFMDUSLifeMD | -35.34x | 195.82% | $102.67M |
RNLXYUSRENALYTIX PLC SPON ADS EACH REP 50 ORD (POST SPLIT) | -2.34x | -- | $46.49M |
DRIOUSDarioHealth | -5.28x | 62.43% | $36.92M |
ONMDUSOneMedNet | -3.31x | -- | $27.92M |
ITOCUSiTonic | -2.30x | -- | $20.48M |
AIFFUSFirefly Neuroscience | -1.53x | -- | $14.43M |
BFRGUSBullfrog AI | -1.53x | 41.27% | $9.16M |
HLYKUSHealthLynked Corp. | -1.55x | -- | $6.21M |
ACONUSAclarion | -0.60x | 65.17% | $5.56M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
